中央静脉征作为多发性硬化诊断影像生物标志物的评估
这项多中心横断面研究纳入606例参与者,评估3T MRI上中央静脉征区分多发性硬化(MS)与非MS的敏感性和特异性。使用35%中央静脉征比例阈值时敏感性68.1%、特异性82.9%;三种中央静脉征病灶标准敏感性61.9%、特异性89.0%。
要点
- 3T MRI中央静脉征区分MS与非MS特异性高、敏感性中等。
- 35%比例阈值下敏感性68.1%、特异性82.9%。
- 三种中央静脉征病灶标准敏感性61.9%、特异性89.0%。
核心结论
- 3T MRI上使用中央静脉征区分MS与非MS具有高特异性和中等敏感性。
- 可能需要国际多中心研究以确认基于中央静脉征的标准能否准确检测MS。
研究设计与样本
- 多中心横断面研究,最终纳入606例参与者,来自欧洲8个神经影像中心的观察性研究及神经影像研究数据库。
- 采用新型盲法程序使研究者对参与者诊断保持盲态。
主要发现
- 共分析487例患者的4447个病灶,包括临床孤立综合征98例690个病灶、复发缓解型MS 225例2815个病灶等。
- 使用35%中央静脉征比例阈值区分MS与非MS的敏感性为68.1%、特异性为82.9%。
- 三种中央静脉征病灶标准的敏感性为61.9%、特异性为89.0%。
- 使用优化的T2*加权序列时敏感性更高。
关键数值与推荐
- 中央静脉征在3T T2*加权或磁敏感加权成像上检测。
- 中央静脉征病灶标准由中央静脉征病灶比例或绝对数量定义。
- 35%中央静脉征比例阈值:敏感性68.1%、特异性82.9%。
- 三种中央静脉征病灶标准:敏感性61.9%、特异性89.0%。
临床怎么用
- 3T脑MRI中央静脉征可用于辅助区分MS与非MS,尤其适用于特异性要求高的鉴别场景。
- 采用35%比例阈值或三种病灶标准时需注意敏感性中等,阴性结果不能完全排除MS。
- 优化T2*加权序列可提高敏感性。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The central vein sign has been proposed as a specific imaging biomarker for distinguishing between multiple sclerosis (MS) and not MS, mainly based on findings from ultrahigh-field magnetic resonance imaging (MRI) studies. The diagnostic value of the central vein sign in a multicenter setting with a variety of clinical 3 tesla (T) MRI protocols, however, remains unknown. OBJECTIVE: To evaluate the sensitivity and specificity of various central vein sign lesion criteria for differentiating MS from non-MS conditions using 3T brain MRI with various commonly used pulse sequences. DESIGN, SETTING, AND PARTICIPANTS: This large multicenter, cross-sectional study enrolled participants (n = 648) of ongoing observational studies and patients included in neuroimaging research databases of 8 neuroimaging centers in Europe. Patient enrollment and MRI data collection were performed between January 1, 2010, and November 30, 2016. Data analysis was conducted between January 1, 2016, and April 30, 2018. Investigators were blinded to participant diagnosis by a novel blinding procedure. MAIN OUTCOMES AND MEASURES: Occurrence of central vein sign was detected on 3T T2*-weighted or susceptibility-weighted imaging. Sensitivity and specificity were assessed for these MRI sequences and for different central vein sign lesion criteria, which were defined by the proportion of lesions with central vein sign or by absolute numbers of lesions with central vein sign. RESULTS: A total of 606 participants were included in the study after exclusion of 42 participants. Among the 606 participants, 413 (68.2%) were women. Patients with clinically isolated syndrome and relapsing-remitting MS (RRMS) included 235 women (66.6%) and had a median (range) age of 37 (14.7-61.4) years, a median (range) disease duration of 2 (0-33) years, and a median (range) Expanded Disability Status Scale score of 1.5 (0-6.5). Patients without MS included 178 women (70.4%) and had a median (range) age of 54 (18-83) years. A total of 4447 lesions were analyzed in a total of 487 patients: 690 lesions in 98 participants with clinically isolated syndrome, 2815 lesions in 225 participants with RRMS, 54 lesions in 13 participants with neuromyelitis optica spectrum disorder, 54 lesions in 14 participants with systemic lupus erythematosus, 121 lesions in 29 participants with migraine or cluster headache, 240 lesions in 20 participants with diabetes, and 473 lesions in 88 participants with other types of small-vessel disease. The sensitivity was 68.1% and specificity was 82.9% for distinguishing MS from not MS using a 35% central vein sign proportion threshold. The 3 central vein sign lesion criteria had a sensitivity of 61.9% and specificity of 89.0%. Sensitivity was higher when an optimized T2*-weighted sequence was used. CONCLUSIONS AND RELEVANCE: In this study, use of the central vein sign at 3T MRI yielded a high specificity and a moderate sensitivity in differentiating MS from not MS; international, multicenter studies may be needed to ascertain whether the central vein sign-based criteria can accurately detect MS.
引用
- Sinnecker T, Clarke MA, Meier D, et al. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. JAMA Neurol. 2019. PMID: 31424490. doi:10.1001/jamaneurol.2019.2478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。